OBJECTIVES: To investigate the association between inflammatory mediators, matrix degrading enzymes and acute coronary syndrome (ACS) and the impact of early reperfusion therapy on circulating biomarkers. DESIGN: Peripheral serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were determined in 134 patients with ACS. These biomarkers were serially monitored in ten patients with intravenous thrombolytic therapy (IVT). RESULTS: Serum levels of IL-6, hs-CRP and MMP-9 were higher in unstable angina (UA) and myocardial infarction (MI) groups than in control or SA group (p<0.05). Peripheral IL-6 level in patients with MI was greater after percutaneous coronary intervention (PCI) (p<0.01) or IVT (p<0.05). Serial concentration determination revealed marked elevation of serum IL-6 and MMP-9 levels, both reaching peak values (like creatine kinase-MB). CONCLUSIONS: Elevated levels of IL-6, hs-CRP and MMP-9 provide a link between inflammation, matrix degradation and the development and progression of ACS. IL-6 and MMP-9 appear to be released mainly from vulnerable plaque or necrotic myocardium during the acute phase of MI.
OBJECTIVES: To investigate the association between inflammatory mediators, matrix degrading enzymes and acute coronary syndrome (ACS) and the impact of early reperfusion therapy on circulating biomarkers. DESIGN: Peripheral serum levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were determined in 134 patients with ACS. These biomarkers were serially monitored in ten patients with intravenous thrombolytic therapy (IVT). RESULTS: Serum levels of IL-6, hs-CRP and MMP-9 were higher in unstable angina (UA) and myocardial infarction (MI) groups than in control or SA group (p<0.05). Peripheral IL-6 level in patients with MI was greater after percutaneous coronary intervention (PCI) (p<0.01) or IVT (p<0.05). Serial concentration determination revealed marked elevation of serum IL-6 and MMP-9 levels, both reaching peak values (like creatine kinase-MB). CONCLUSIONS: Elevated levels of IL-6, hs-CRP and MMP-9 provide a link between inflammation, matrix degradation and the development and progression of ACS. IL-6 and MMP-9 appear to be released mainly from vulnerable plaque or necrotic myocardium during the acute phase of MI.
Authors: Spyridon G Deftereos; Frans J Beerkens; Binita Shah; George Giannopoulos; Dimitrios A Vrachatis; Sotiria G Giotaki; Gerasimos Siasos; Johny Nicolas; Clare Arnott; Sanjay Patel; Mark Parsons; Jean-Claude Tardif; Jason C Kovacic; George D Dangas Journal: Circulation Date: 2021-12-29 Impact factor: 29.690
Authors: Binita Shah; Michael Pillinger; Hua Zhong; Bruce Cronstein; Yuhe Xia; Jeffrey D Lorin; Nathaniel R Smilowitz; Frederick Feit; Nicole Ratnapala; Norma M Keller; Stuart D Katz Journal: Circ Cardiovasc Interv Date: 2020-04-16 Impact factor: 6.546
Authors: Michael J Hobson; Paul W Hake; Michael O'Connor; Christine Schulte; Victoria Moore; Jeanne M James; Giovanna Piraino; Basilia Zingarelli Journal: Shock Date: 2014-01 Impact factor: 3.454
Authors: Oksana S Pogorielova; Viktoriia V Korniienko; Yaroslav D Chumachenko; Olha A Obukhova; Igor Martsovenko; Viktoriia Yu Harbuzova Journal: Cardiol Res Pract Date: 2022-04-11 Impact factor: 1.990
Authors: Nouf M Al-Rasheed; Maha M Al-Oteibi; Reem Z Al-Manee; Sarah A Al-Shareef; Nawal M Al-Rasheed; Iman H Hasan; Raeesa A Mohamad; Ayman M Mahmoud Journal: Drug Des Devel Ther Date: 2015-06-23 Impact factor: 4.162
Authors: Karlheinz Peter; Philipp Diehl; Patrick Malcolm Siegel; Judith Schmich; Georg Barinov; István Bojti; Christopher Vedecnik; Novita Riani Simanjuntak; Christoph Bode; Martin Moser Journal: J Thromb Thrombolysis Date: 2020-10 Impact factor: 2.300